Peter J. Allen

This study identifies PDAC cancer cell subpopulations using multiplexed glycan immunofluorescence and shows consistent aberrant glycan signatures in both tumor and blood samples, improving detection beyond CA19-9 alone.

This paper uses spatial transcriptomics to identify low-risk and high-risk expression programs in IPMN that correlate with exocrine and basal-like PDAC signatures, improving risk stratification.